《大行報告》里昂下調耐世特(01316.HK)目標價至14元 評級「買入」
里昂發表報告,下調耐世特(01316.HK)核心利潤預期,因為在更多的芯片短缺影響下,今年的銷售額預計會下降,然後到2022年至2023年恢復。目標價由14.3元下調至14元,相等於2022年至2023年平均市盈率預測16倍,維持評級「買入」。
里昂指,隨著銷售恢復,耐世特上半年的利潤在去年低基數下躍升,但芯片短缺問題可能會延續到下半年,而物流成本居高不下亦會影響利潤表現。隨著管理層努力解決相關問題,加上電氣化和高級駕駛輔助系統(ADASs)等主要趨勢應推動產品升級,相信能支持其長期增長和增加市場份額。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.